1 InteRNAtional Human Genome Sequencing Consortium. Fishing the euchromatic sequence of the human genome. Nature, 431: 931-945 (2004)
2 The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature, 489: 57-74 (2012)
3 Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al. Landscape of transcription in human cells. Nature, 489: 101-108 (2012)
4 Cheng J, Kapranov P, Drenknow J, Dike S, Brubaker S, Patel S, Long J, Stern D, Tammana H, Helt G, et al. Transcriptional maps of 10 human chromosomes at 5-Nucleotide resolution. Science, 308: 1149-1154 (2005)
5 Carninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, et al. The transcriptional landscape of the mammalian genome. Science, 309: 1559-1563 (2005)
6 Ma C, Liu Y, He L. microRNAs-powerful repression comes from small RNAs. Sci China C Life Sci., 52: 323-330 (2009)
7 新飯田 俊平 新たな核酸創薬への期待 科学技術動向 7・8 月号 (2011)
8 落合 孝広 microRNA が制御する多彩な生命現象とがん研究の接点 実験医学 27: 1188- 1193 (2009)
9 Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA, 103 : 2257 (2006)
10 Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res., 22: 1775-1789 (2012)
11 Mercer TR, Mattick JS. Structure and function of long noncoding RNAs in epigenetic regulation. Nat Struct Mol Biol., 20: 300-307 (2013)
12 岡本郁弘. 「長鎖 ncRNA 研究の源流である Xist の既知・未知」 (岡本郁弘) 実験医学, 29 : 1728-1734 (2011)
13 Naganuma T, Hirose T. Paraspeckle formation during the biogenesis of long non-coding RNAs. RNA Biol., 10 (3): 456-461 (2013)
14 Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer., 10: 38 (2011)
15 Gupta RA, Shah N, Wang KC, Kim J, HorlingshM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B, West RB, van de Vijver MJ, Sukumar S, Chang HY. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 464: 1071-1076 (2010)
16 Yang L, Duff MO, Graveley BR, Carmichael GG, Chen LL. Genomewide characterization of nonpolyadenylated RNAs. Geno Biol., 12: R16 (2011)
17 Yin QF, Yang L, Zhang Y, Xiang JF, Wu YW, Carmichael CG, Chen LL. Long noncoding RNAs with snoRNA ends. Mol Cell., 48: 219-230 (2012)
18 Kapranov P, Cheng J, Dike S, Nix DA, Duttaqupta R, Willingham AT, Stadler PF, Hertel J, Hackemuller J, Hofacker IL et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science., 316: 1484-1488 (2007)
19 Novikova IV, Hennelly SP, Tung CS, Sanbonmatsu KY. Rise of the RNA machines: exploring the structure of long non-coding RNAs. J Mol Biol., 425: 3731-3746 (2013)
20 Nakagawa S. Lessons from reverse-genetic studies of lncRNAs. Biochim Ciophys Acta.,15: 0-6 (2015)
21 Kudo S, Tamura S, Hirota S, Sano Y, Yamano H, Serizawa M, Fukuoka T, Mitsuoka H, Nakajima T, Kusaka H. The problem of de novo colorectal carcinoma. Eur J Cancer., 31A: 1118-1120 (1995)
22 Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science., 307: 1904- 1909 (2005)
23 Van Cutsem E, Borras JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ, Tabernero J. Improving outcomesin colorectal cancer: where do we go from here? Eur J Cancer., 49: 2476-2485 (2013)
24 がん統計白書
25 大腸がん研究会 HP （http://www.jsccr.jp/index.html）
26 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr., PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med., 26: 2509-2520 (2015)
27 Koizumi M. 2’-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents. Biol Pharm Bull., 27: 453-456 (2004)
28 Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, Ambegia E, McClintock K, MacLchlan I. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest., 119: 661-673 (2009)
29 Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell., 84: 345-357 (1996)
30 「Review β カテニン」（小沢政之）蛋白質核酸酵素, 46: 197-207 (2001)
31 Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R., Lack of beta-catenin affects mouse development at gastrulation. Development., 121: 3529-3537 (1995)
32 Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C, Birchmeier W., Requirement for beta-catenin in anterior-posterior axis formation in mice. J Cell Biol., 148: 567-578 (2000)
33 「がん抑制遺伝子産物 APC の新しいはたらき」（川崎善博、秋山徹）蛋白質核酸酵素, 46: 228-232 (2001)
34 Bryan T. M., K Tamai, X He., Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases. Developmental Cell., 17: 9-26 (2009)
35 「Wnt シグナル伝達経路の活性制御と発がんとの関連」（山本英樹）生化学; 80: 1079-1093 (2008)
36 Polakis P., The many ways of Wnt in cancer. Curr Opin Genet Develop., 17: 45-51 (2007)
37 Kinzler KW, Vogelstein B., Lessons from hereditary colorectal cancer. Cell., 18: 159-170 (1996)
38 Segditsas S, Tomlinson I., Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene., 57: 7531-7537 (2006)
39 Sang-Kyu Lee, Jeong-Ha Hwang, Kang-Yell Choi., Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis. Advances in Biological Regulation., 68: 46-54 (2018)
40 Kee BL. E and ID proteins branch out. Nat Rev Imunol., 9: 175-184 (2009)
41 Slattery C, Ryan MP, McMorrow T. E2A proteins: regulators of cell phenotype in normal physiology and disease. Int J Biochem Cell Biol., 40: 1431-1436 (2007)
42 Miyazaki M, Rivera RR, Miyazaki K, Lin YC, Agata Y, Murre C. The opposing roles of the transcription factor E2A and its antagonist Id3 that orchestrate and enforce the naïve fate of T cells. Nat Immunol., 12: 992-1001 (2011)
43 Seidel MG, Look AT., E2A-HLF usurps control of evolutionarily conserved survival pathways. Oncogene., 20: 5718-5725 (2001)
44 Aspland SE, Bendall HH, Murre C., The role of E2A-PBX1 in leukemogenesis. Oncogene., 20: 5708-5717 (2001)
45 Kijanka G, Hector S, Kay EW, Murray F, Cummins R, Murphy D, MacCraith BD, Prehn JH, Kenny D., Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut., 59: 69-78 (2010)
46 Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH, Shew JY, Chang KJ, Lee EY, Lee WH., miR-495 is upregulated by E12/E47 in breast cancer stem cell, and promotes oncogenesis and hypoxia resistance via down regulation of E-cadherin and REDD1. Oncogene., 30: 2463-2474 (2011)
47 Patel D, Chaudhary J., Increased expression of bHLH transcription factor E2A in prostate cancer promotes proliferation and confers resistance to doxorubicin induced apoptosis. Biochem Biophys Res Commun., 422: 146-151 (2012)
48 Thompson MR, Xu D, Williams BR. ATF3 transcription factor and its emerging roles in immunity and cancer. J Mol Med (Berl)., 87: 1053-1060 (2009)
49 Hai T, Wolfgang CD, Marsee DK, Allen AE, Sivaprasad U., ATF3 and stress responses. Gene Expr. 7: 321-335 (1999)
50 Hai T, Hartman MG., The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene., 273: 1-11 (2001)
51 Bottone FG Jr, Martinez JM, Collins JB, Afshari CA, Eling TE. Gene modulation by the cyclooxygenase inhibitor, sulindac sulfide, in human colorectal carcinoma cells: possible link to apoptosis. J Biol Chem., 278: 25790-25801 (2003)
52 Hackl C, Lang SA, Moser C, Mori A, Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler EK, Stoeltzing O. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer., 10: 668 (2010)
53 Winkler GS., The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol., 222: 66-72 (2010)
54 Lin TY, Cheng YC, Yang HC, Lin WC, Wang CC, Lai PL, Shieh SY., Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis. Oncogene, 31: 3287-3297 (2012)
55 Oy YH, Chung PH, Hsu FF, Sun TP, Chang WY, SHieh SY., The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J., 26: 3968-3980 (2007)
56 Yoshida Y, Hosoda E, Nakamura T, Yamamoto T., Association of ANA, a member of the antiproliferative Tob family proteins, with a Caf1 component of the CCR4 transcriptional regulatory complex. Jpn J Cancer Res., 92: 592-6 (2001)
57 Majid S, Dar AA, Ahmad AE, Hirata H, Kawakami K, Shahryari V, Saini S, Tanaka Y, Dahiya AV, Khatri G, Dahiva R. BTG tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis, 30: 662-670 (2009)
58 Yoneda M, Suzuki T, Nakamura T, Ajima R, Yoshida Y, Kakuta S, Katsuko S, Iwakura Y, Shibutani M, Mitsumori K, Yokota J, Yamamoto T. Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma. Cancer Sci., 100: 225-232 (2009)
59 Yanagida S, Taniue K, Sugimasa H, Nasu E, Takeda Y, Kobayashi M, Yamamoto T, Okamoto A, Akiyama T. ASBEL, an ANA/BTG3 antisense transcript required for tumorigenicity of ovarian carcinoma. Sci Rep., 3: 1305 (2013)
60 Bomsztyk K, Denisenko O, Ostrowski J. hnRNPK: One protein multiple processes. Bioessays., 26: 629-638 (2004)
61 Barboro P, Ferrari N, Balbi C. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression., 352: 152-159 (2014)
62 Moumen A, Masterson P, O’Connor MJ, Jackson SP. hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage. Cell., 123: 1065-1078 (2005)
63 Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F,Balbi C. Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4‐hydroxy‐tamoxifen in prostatic cancer cell lines. The prostate., 71: 1466-1479 (2011)
64 Lubelsky Y and Ulitsky I. Seauences enriched in Alu repeats drive nuclear localization of long RNAs in human cells. Nature., 555: 107-125 (2018)
65 Kawasaki Y, Komiya M, Matsumura K, Negishi L, Suda S, Okuno M, Yokota N, Osada T, Nagashima T, Hiyoshi M, et al. MYU, a Target lncRNA for Wnt/c-Myc Signaling, Mediates Induction of CDK6 to Promote Cell Cycle Progression. Cell Reports., 16: 2554-2564 (2016)
66 Kim T, Jeon YJ, Cui R, Lee JH, Peng Y, Kim SH, Tili E, Alder HCroce CM. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis., 107 (2015) doi: 10.1093/jnci/dju505
67 Ali MM, Akhade VS, Kosalai ST, Subhash S, Statello L, Meryet-Figuiere M, Abrahamsson J, Mondal T, Kanduri C. PAN-cancer analysis of S-phase enriched lncRNAs identifies oncogenic drivers and biomarkers. Nature Communications., 9: 1-20 (2018)
68 Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Clifford lane H, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Research., 35: W169-W175 (2007)
69 Bottone FG Jr, Moon Y, Kim JS, Alston-Mills B, Ishibashi M, Eling TE. The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther., 4: 693-703 (2005)
70 Yin X, DeWille JW, Hai T. A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene, 27: 2118-2127 (2008)
71 Pelzer AE, Bektic J, Haag P, Berger AP, Pycha A, Schafer G, Rogatsch H, Horninger W, Bartsch G, Klocker H. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol., 175: 1517-1522 (2006)
72 Ling MT, Wang X, Zhang X, Wong YC. The multiple roles of Id-1 in cancer progression. Differentiation, 74: 481-487 (2006)
73 Beckmann BM, Horos R, Fischer B, Castello A, Eichelbaum K, Alleaume AM, Schwarzl T, Curk T, Foehr S, Huber W, Krijgsveld J, Hentze MW. The RNA-binding proteomes from yeast to man harbor conserved enigmRBPs. Nat Commun., 6: 10127 (2015)
74 Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P, Rothballer A, Ascano M, Jungkamp AC, Munschauer M, Ulrich A, Wardle GS, Dewell S, Zavolan M, Tuschl T. PAR-CliP— a method to identify transcriptome-wide the binding sites of RNA binding proteins. J Vis Exp., 41: 2-6 (2010)
75 Sundin LJ, Guimaraes GJ, Deluca JG. The NDC80 complex proteins Nuf2 and Hec1 make distinct contributions to kinetochore-microtubule attachment in mitosis. Mol. Biol. Cell. 22: 759-768 (2011)
76 Cheeseman IM, Chappie JS, Wilson-Kubalek EM, Desai A. The conserved KMN network constitutes the core microtubule-binding site of the kinetochore. Cell. 127: 983-997 (2006)
77 Ding Y, Herman JA, Toledo CM, Lang JM, Corrin P, Girard EJ, Basom R, Delrow JJ, Olson JM, Paddison PJ. ZNF131 suppresses centrosome fragmentation in glioblastoma stem-like cells through regulation of HAUS5. Oncotarget. 30: 48545-48562 (2017)
78 Sun C, Huang S, Ju W, Hou Y, Wang Z, Liu Y, Wu L, He X. Elevated DSN1 expression is associated with poor survival in patients with hepatocellular carcinoma. Human Pathology. 81: 113-120 (2018)
論文の公開元へ
